304 related articles for article (PubMed ID: 22001945)
1. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
Bow EJ
Curr Opin Infect Dis; 2011 Dec; 24(6):545-53. PubMed ID: 22001945
[TBL] [Abstract][Full Text] [Related]
2. Management of the febrile neutropenic patient.
Picazo JJ;
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
[TBL] [Abstract][Full Text] [Related]
3. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
5. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
Sinkó J; Cser V; Konkoly Thege M; Masszi T
Orv Hetil; 2011 Jul; 152(27):1063-7. PubMed ID: 21676672
[TBL] [Abstract][Full Text] [Related]
6. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
7. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
8. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications.
Bonadio M; Morelli G; Mori S; Riccioni R; Papineschi F; Petrini M
Biomed Pharmacother; 2005 Oct; 59(9):511-6. PubMed ID: 16274955
[TBL] [Abstract][Full Text] [Related]
11. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients.
Cruciani M; Malena M; Bosco O; Nardi S; Serpelloni G; Mengoli C
J Clin Oncol; 2003 Nov; 21(22):4127-37. PubMed ID: 14615441
[TBL] [Abstract][Full Text] [Related]
12. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
Cattaneo C; Quaresmini G; Casari S; Capucci MA; Micheletti M; Borlenghi E; Signorini L; Re A; Carosi G; Rossi G
J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
[TBL] [Abstract][Full Text] [Related]
13. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
14. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
[TBL] [Abstract][Full Text] [Related]
15. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
Cooper MR; Durand CR; Beaulac MT; Steinberg M
Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
[TBL] [Abstract][Full Text] [Related]
16. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Slavin MA; Lingaratnam S; Mileshkin L; Booth DL; Cain MJ; Ritchie DS; Wei A; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):102-9. PubMed ID: 21272174
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Leibovici L; Paul M; Cullen M; Bucaneve G; Gafter-Gvili A; Fraser A; Kern WV
Cancer; 2006 Oct; 107(8):1743-51. PubMed ID: 16977651
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
19. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002.
Lee K; Kim YA; Park YJ; Lee HS; Kim MY; Kim EC; Yong D; Chong Y;
Yonsei Med J; 2004 Aug; 45(4):598-608. PubMed ID: 15344199
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
